This section of the website contains information that should be considered accurate as of the date presented. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Quest Diagnostics is not obligated to update the information contained in this section of the website.
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today the early tender results of its previously announced cash tender offers...
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today the determination of the pricing for its previously announced cash...
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the availability of Neurome™, a whole exome sequencing service designed to aid the...
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it is amending the terms of its cash tender offers (each, an...
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it intends to offer $1,200,000,000 in aggregate principal amount...
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it has commenced cash tender offers (each, an "Offer" and,...
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Barclays Global Healthcare Conference in...
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has been named a "Most Admired Company" by Fortune Magazine in the "Health...
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it and Myriad Genetics Inc. have reached an agreement that ends their BRCA...
Fourth quarter revenues from continuing operations of $1.9 billion, up 7.2% versus prior year Adjusted diluted EPS from continuing operations of $1.08, up 4.9% versus prior year Reported diluted...